IELSG37 - A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell
Persone
(Responsabile)
Informazioni aggiuntive
Acronimo
IELSG37
Data d'inizio
01.04.2013
Data di fine
31.03.2016
Durata
36 Mesi
Enti finanziatori
SNSF
Stato
Concluso
Categoria
Swiss National Science Foundation /
Project Funding /
Mathematics, Natural and Engineering Sciences (Division II)